To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
5 Current news of Takeda
rss
Evotec to Collaborate with Takeda Cambridge for Multi-target Hit Identification
01-24-2011
Evotec AG announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases.Evotec will apply its state-of-the-art Screening Platform and proprietary GPCR ...
Approval of Additional Indication of NESINA: Combination Therapy with Thiazolidinediones for Type 2 Diabetes in Japan
08-24-2010
Takeda Pharmaceutical Company Limited announced that an additional indication for “NESINA®” (generic name: Alogliptin), combination therapy with thiazolidinediones for type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare. NESINA, a dipeptidyl peptidase-IV ...
Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin for Treatment of Type 2 Diabetes
08-31-2009
Takeda Pharmaceutical Company Limited and Takeda Global Research & Development Center, Inc., a wholly owned United States subsidiary, jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a ...
Takeda Reacquires Rights to Diabetes Drug in Canada
08-25-2009
Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in ...
Kinaxo Biotechnologies Enters Agreement with Takeda
04-23-2008
Kinaxo Biotechnologies announced that it has entered an agreement with Takeda San Diego, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Osaka, Japan. Under the agreement, Kinaxo will make its KinaTor(TM) technology available to Takeda researchers involved in drug ...
Page 1 From 1
